Interleukin Genetics Receives NYSE Amex Staff Determination, Requests Oral Hearing...

Interleukin Genetics Receives NYSE Amex Staff Determination, Requests Oral
Hearing Before the Listing Qualifications Panel

WALTHAM, Mass., March 30 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc.
(NYSE Amex: ILI) announced today that the NYSE Amex LLC (formerly known as the
NYSE Alternext US and the American Stock Exchange) has issued a delisting
notification to the Company as it has not accepted the plan as drafted and
filed in January detailing how the Company intends to regain compliance with
Section 1003(a)(iii) of the Exchange's Company Guide by June 23, 2010. The
Company has appealed this determination and requested an oral hearing before a
committee of the Exchange, which it expects to be scheduled within the next 45
days. The Company will remain listed on the exchange at least until such
appeal has been heard.

"We are eager to present in person to the Listing Qualifications Panel to
address their questions on our plan. Written documents may not effectively
convey the tremendous opportunities for genetic testing across consumer, drug
development and clinical diagnostic channels. Interleukin Genetics is now in
a leadership position in this field, as over the past year the Company has
focused on putting the necessary resources in place to excel in these
markets," said Lewis H. Bender, Chief Executive Officer. "The Company has
strengthened its management team, refined its focus, renegotiated restrictive
agreements and executed on other core deliverables. The results of these
efforts are just now beginning to be realized. We are preparing for a Q2
launch of our own genetic test brands and continue to aggressively push to
partner our intellectual property and genetic biomarker expertise with
additional biotechnology and pharmaceutical companies. We have some new
partnerships in place and the capital resources available to fund our
operations through the Exchange's monitoring date of June 23, 2010."

As previously disclosed, on December 23, 2008 the Company received notice from
the Exchange indicating that the Company is not in compliance with Section
1003(a)(iii) of the Company Guide because its stockholders' equity is less
than $6,000,000, and it has had losses from continuing operations and net
losses in its five most recent fiscal years. As of December 31, 2008, the
Company's stockholders' equity was approximately $4.5 million.

If the Listing Qualifications Panel accepts the Company's plan based on
appeal, the Company may be able to continue its listing through June 23, 2010
or such other period as determined by the Exchange, during which time the
Company will be subject to periodic review to determine if it is making
progress consistent with the plan. There can be no assurance that the hearing
(to be scheduled) will be decided in favor of the Company, that the Company's
plan will be acceptable or that if such plan is accepted, that the Company
will be able to make progress consistent with such plan. In that event, the
Company believes that its securities will be eligible to trade or be quoted on
alternative markets.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI) is a healthcare company that
specializes in the development of genetic biomarker tests for the emerging
personalized health market. The Company is focused on the future of health and
medicine. Interleukin Genetics uses its leading genetics research and
scientific capabilities to develop and commercialize innovative diagnostic and
risk assessment genetic tests. These products could help to improve an
individual's understanding of needed lifestyle changes or of therapeutic
products that can be used to better manage his or her health. Interleukin
Genetics has developed and commercialized genetic tests for risk assessment of
coronary artery disease, periodontal disease, and general nutrition. Through
its Alan James Group subsidiary, the Company also currently offers an array of
Nutraceutical and OTCeuticals(R) products, including Ginkoba(TM), Ginsana(R)
and Venastat(R) which are sold at the nation's largest food, drug and mass
retailers. Interleukin Genetics is headquartered in Waltham, MA. For more
information about Interleukin Genetics and its ongoing programs, please visit
www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including
statements regarding our ability to develop diagnostic, personalized
nutritional and therapeutic products to prevent or treat diseases of
inflammation and other genetic variations, our ability to screen nutritional
compounds for their effects on inflammatory responses and other genetic
variations, given specific genetic patterns and our ability to make progress
in advancing our core technologies. Because such statements include risks and
uncertainties, actual results may differ materially from those expressed or
implied by such forward-looking statements. Factors that could cause actual
results to differ materially from those expressed or implied by such
forward-looking statements include, but are not limited to, our ability to
regain compliance with Section 1003(a)(iii) of the NYSE Amex LLC Company
Guide, the risk of market acceptance of our products, the risk of technology
and product obsolescence, delays in product development, the performance of
our commercial partners, the availability of adequate capital, the actions of
our competitors and other competitive risks, and those risks and uncertainties
described in our annual report on Form 10-K for the year ended December 31,
2008 as amended, filed with the Securities and Exchange Commission, our
quarterly reports on Form 10-Q and other filings made by us with the
Securities and Exchange Commission. We disclaim any obligation or intention to
update these forward-looking statements.

SOURCE Interleukin Genetics, Inc.

Media: Erin Walsh of Interleukin Genetics, +1-781-419-4707,
ewalsh@ilgenetics.com, or Investor Relations: Melanie Friedman of Stern
Investor Relations, +1-212-362-1200, melanie@sternir.com